Zur Frage der Erhaltungstherapie bei Patientinnen mit metastasierendem Mammakarzinom in Remission

  • G. A. Nagel
  • H.-E. Wander
  • H.-H. Bartsch
  • J.-H. Beyer
  • W. Holtkamp
  • D. Meyer
  • P. Schuff-Werner
  • C. Unger
Conference paper

Zusammenfassung

Obwohl sich bei der Behandlung von Patientinnen mit fortgeschrittenem metastasierendem Mammakarzinom die Frage, wie therapeutisch bei Erreichen einer stabilen Remission verfahren werden soll, immer wieder stellt, gibt es bis heute keine systematischen Untersuchungen zum Thema der Erhaltungstherapie.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Brambilla C, Delena M, Rossi A, Valagussa P, Bonadonna G (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1:801–804PubMedCrossRefGoogle Scholar
  2. 2.
    Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, et al. (1978) A Randomized Comparative Trial of Adriamycin versus Methotrexate in Combination Drug Therapy. Cancer 41:1649–1657PubMedCrossRefGoogle Scholar
  3. 3.
    Campbell FC, Blarney RW, Elston CW, Nicholson RI, Griffiths K, et al. (1979) Oestrogenreceptor status and sites of metastasis in breast cancer. Cancer 44:665–670CrossRefGoogle Scholar
  4. 4.
    Carbone PP, Bauer M, Band P, Tormey D (1977) Chemotherapy of disseminated breast cancer. Cancer 39:2916–2922PubMedCrossRefGoogle Scholar
  5. 5.
    Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, et al. (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 51:581–588PubMedCrossRefGoogle Scholar
  6. 6.
    Creech RH, Catalano RB, Harris DT, Engstrom PF, Grotzinger PR (1979) Low Dose Chemotherapy of Metastatic Breast Cancer with Cyclophosphamide, Adriamycin, Methotrexate, 5-Fluorouracil (CAMF) versus sequential Cyclophosphamide, Methotrexate, 5-Fluorouracil (CMF) and Adriamycin. Cancer 43:51–59PubMedCrossRefGoogle Scholar
  7. 7.
    Decker DA, Ahmann DL, Bisel HF, Edmonson JH, Hahn RG, et al. (1979) Complete responders to chemotherapy in metastatic breast cancer. J Amer med Assoc 242:2075–2079CrossRefGoogle Scholar
  8. 8.
    Engelsman E (1983) Therapy of advanced breast cancer: a review. Eur J Cancer Clin Oncol 19:1775–1778PubMedCrossRefGoogle Scholar
  9. 9.
    Falkson G, Falkson HC (1981) A five-drug combination in the treatment of metastatic breast cancer. Cancer Clin Trials 4:81–85PubMedGoogle Scholar
  10. 10.
    Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP, et al. (1985) The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56:219–224PubMedCrossRefGoogle Scholar
  11. 11.
    Feldman L, Hortogayi G, Buzdar A, Blumenschein G, Haynie T (1984) Duration of chemotherapy to achieve complete remission (CR). A prognostic factor in metastatic breast cancer (MBC). ASCO-Abstract C-475Google Scholar
  12. 12.
    Fey MF, Brunner KW, Sonntag RW (1981) Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4:237–247PubMedGoogle Scholar
  13. 13.
    Fischer J, Rose CJ, Rubens RD (1982) Duration of complete response to chemotherapy in advanced breast cancer. Eur J Cancer Clin Oncol 18:747–754PubMedCrossRefGoogle Scholar
  14. 14.
    Freedman LS, Edwards DN, McConnell EM, Downham DY (1979) Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer 40:44–55PubMedCrossRefGoogle Scholar
  15. 15.
    Gewirtz AM, Cadman E (1981) Preliminary Report on the Efficacy of Séquentiel Methotrexate and 5-Fluorouracil in Advanced Breast Cancer. Cancer 47:2552–2555PubMedCrossRefGoogle Scholar
  16. 16.
    Henderson C (1983) Chemotherapy of breast cancer. Cancer 51:2553–2559PubMedCrossRefGoogle Scholar
  17. 17.
    Henderson C, Canellos GP (1980) Cancer of the breast. The past decade (second of two parts). N Engl J Med 302:78–90PubMedCrossRefGoogle Scholar
  18. 18.
    Henderson C, Gelman R, Canellos GP, Frei E III Prolonged disease-free survival in advanced breast cancer treated with „super-CMF“Adriamycin: an alternating regimen employing high-dose Methotrexate with citrovorum factor rescue. Cancer Treat Rep 65 (Suppl 1):65–75Google Scholar
  19. 19.
    Hirshaut Y, Kesselheim H (1983) Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity. Cancer 51:1998–2004PubMedCrossRefGoogle Scholar
  20. 20.
    Howell A, Barnes DM, Harland RNL, Redford J, Bramwell VHC, et al. (1984) Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1:588–591PubMedCrossRefGoogle Scholar
  21. 21.
    Karabali-Dalamaga S, Souhami RL, Ottiggins NJ, Soumilas A, Clark CG (1978) Natural history and prognosis of recurrent breast cancer. Br Med J 2:730–733PubMedCrossRefGoogle Scholar
  22. 22.
    Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, et al. (1979) Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Int Med 91:847–852PubMedGoogle Scholar
  23. 23.
    Manni A, Trujillo JE, Pearson OH (1980) Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: Effects on survival. Cancer Treat Rep 64:111–116PubMedGoogle Scholar
  24. 24.
    Mattson W, Eyben FV, Hallstein L, Bjelkengren G (1982) A phase II study of combined 5-Fluorouracil and Mitomycin C in advanced breast cancer. Cancer 49:217–220CrossRefGoogle Scholar
  25. 25.
    Mattsson W, Arwidi A, von Eyben F, Lindholm CE (1979) Combination chemotherapy in advanced postmenopausal mammary carcinoma. Acta Radiol Oncol 18:431–444CrossRefGoogle Scholar
  26. 26.
    Meyer JS, Rao BR, Stevens SC, White WL (1977) Low indicence of estrogen receptor in breast carcinoma with rapid rates of cellular replications. Cancer 40:2290–2298PubMedCrossRefGoogle Scholar
  27. 27.
    Muss HB, White DR, Richards F, Cooper MR, Stuart JJ, et al. (1978) Adriamycin versus Methotrexate in Five-Drug Combination Chemotherapy for Advanced Breast Cancer. Cancer 42:2141–2148PubMedCrossRefGoogle Scholar
  28. 28.
    Powles TJ, Smith IE, Ford HT, Coombes RC, Jones JM, et al. (1980) Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet I:580–582CrossRefGoogle Scholar
  29. 29.
    Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, et al. (1985) Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 55:541–546CrossRefGoogle Scholar
  30. 30.
    Rossof AH, Gelman R, Creech RH (1982) Randomized evaluation of combination chemotherapy vs. observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal women. Amer J Clin Oncol 5:253–259CrossRefGoogle Scholar
  31. 31.
    Rubens RD, Begent RHJ, Knight RK, Sexton SA, Hayward JL (1978) Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer 42:1680–1686PubMedCrossRefGoogle Scholar
  32. 32.
    Salmon SE, Jones SE (1979) Untersuchungen der Kombination Adriamycin und Cyclophosphamid (allein oder mit anderen Substanzen) zur Behandlung des Mammakarzinoms. Onkologie 2:2CrossRefGoogle Scholar
  33. 33.
    Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, et al. (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer 47:554–560PubMedCrossRefGoogle Scholar
  34. 34.
    Silverstrini R, Daidone MG, DiFronzo G (1979) Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44:665–670PubMedCrossRefGoogle Scholar
  35. 35.
    Spremulli EN, Dexter DL (1983) Human tumor cell heterogeneity and metastasis. J Clin Oncol 1:496–509PubMedGoogle Scholar
  36. 36.
    Stewart JF, Rubens RD, Millis RR, King RJB, Hayward JL (1983) Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur J Cancer Clin Oncol 19:1381–1387PubMedCrossRefGoogle Scholar
  37. 37.
    Straus MJ, Moran RE (1980) The cell cycle kinetics of human breast cancer. Cancer 46:2634–2639PubMedCrossRefGoogle Scholar
  38. 38.
    Swenerton KD, Legha SS, Smith T, Hortogagyi GN, Gehan EA, et al. (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562PubMedGoogle Scholar
  39. 39.
    Valagussa P, Brambilla C, Bonadonna G (1979) Advanced breast cancer: are the traditional stratification parameters still of value when patients are treated with combination chemotherapy. Eur J Cancer 15:565–571PubMedGoogle Scholar
  40. 40.
    Wander HE (1981) Indikationen von Adriamycin beim metastasierenden Mammakarzinom. Beitr Onkol 9:140–149Google Scholar
  41. 41.
    Wander HE, Nagel GA (1984) Nadir-adapted polychemotherapy of metastatic breast cancer (mbc). Verh Dt KrebsGes 5:595Google Scholar
  42. 42.
    Weigand RA (1984) Cellular heterogeneity in human breast cancer. AACR Abstract 214Google Scholar
  43. 43.
    WHO Handbook for reporting results of cancer treatment (1979). SHO Offset Publication No. 48 GenevaGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • G. A. Nagel
  • H.-E. Wander
  • H.-H. Bartsch
  • J.-H. Beyer
  • W. Holtkamp
  • D. Meyer
  • P. Schuff-Werner
  • C. Unger

There are no affiliations available

Personalised recommendations